Risks

Negative interest coverage and a long cash conversion cycle imply financing and working-capital pressure, leaving FBIO more exposed than better-capitalized biotech peers.

Days sales outstanding near 196 days suggest slower cash collection, which can constrain liquidity and operating flexibility versus peers with faster receivables turnover.

Inventory days above 116 and payables days near 169 indicate a stretched operating cycle, increasing execution risk relative to leaner development-stage peers.

A debt-to-equity ratio below 0.4 and negative net debt to EBITDA reduce balance-sheet leverage risk, but peers with stronger earnings still convert that structure into better resilience.

Opportunities

Current and quick ratios near 4.0 indicate ample near-term liquidity, which supports funding continuity versus peers with tighter working-capital cushions.

Negative net debt to EBITDA suggests limited net leverage, giving FBIO more flexibility than indebted peers if capital markets remain selective.

Low debt burden relative to equity can preserve optionality for clinical or portfolio execution, while more levered peers face greater refinancing constraints.

Liquidity strength partially offsets weak operating cash conversion, so FBIO is better positioned than peers that must fund growth under tighter short-term cash conditions.

Overall Score

FBIO’s strong liquidity and low net leverage support resilience versus peers, but negative interest coverage and a stretched cash conversion cycle materially limit forward flexibility.